Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (887 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Process of determining and distinguishing species of bacteria or viruses based on antigens they share.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Serotypings.
Where it fits in the MeSH classification
- Broader topics
- Immunologic Tests; Bacterial Typing Techniques
- See also
- Serogroup
Research landscape
PubMed indexes 27,413 records tagged with the MeSH heading “Serotyping” (counts retrieved 2026-11-04). 836 of them (3.0%) were published from 2020 onward, and the busiest period so far is through 1999 with 15,351 records.
Reviews account for 1,161 records (4.2%) and meta-analyses for 26. Randomized controlled trials number 134 (0.5%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 15,351 |
| 2000-2009 | 6,778 |
| 2010-2019 | 4,448 |
| 2020 onward | 836 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 1,161 | 4.2% |
| Meta-analyses | 26 | 0.1% |
| Randomized controlled trials | 134 | 0.5% |
Method: PubMed query "Serotyping"[MeSH Terms] with publication-type and date filters, retrieved 2026-11-04.
Reading the evidence in diagnostics and medical technology
A test or device is judged by how well it detects a condition, how often it gives false alarms or misses cases, and whether using it improves outcomes for people. Accuracy depends on who is tested and how common the condition is, so a test that performs well in a specialist hospital can perform differently in the community. Check the reference standard, the population studied, the sensitivity and specificity and whether results were confirmed in a separate group.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain | 2013 | Research article Design not recorded in structured metadata | 171 | cc by PMID 23825679 · DOI · PMC3692458 |
| CRISPR typing and subtyping for improved laboratory surveillance of Salmonella infections | 2012 | Research article Design not recorded in structured metadata | 168 | cc by PMID 22623967 · DOI · PMC3356390 |
| SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data | 2018 | Research article Design not recorded in structured metadata | 135 | cc by PMID 29870330 · DOI · PMC6113868 |
| Accurate serotype identification of Streptococcus pneumoniae using nanopore Cas9-targeted serotype identification (nCATSerotyping) | 2026 | Research article Design not recorded in structured metadata | 1 | cc by PMID 41467797 · DOI · PMC12892971 |
Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Adeno-associated virus (AAV) mediated gene expression is a powerful tool for gene therapy and preclinical studies.
- Closing excerpt
- This study demonstrates that both capsid serotype and timing of injection influence the regional and cell-type distribution of AAV in neonatal rodents, and emphasizes the utility of pseudotyped AAV vectors for translational gene therapy paradigms.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (206 words)
Adeno-associated virus (AAV) mediated gene expression is a powerful tool for gene therapy and preclinical studies. A comprehensive analysis of CNS cell type tropism, expression levels and biodistribution of different capsid serotypes has not yet been undertaken in neonatal rodents. Our previous studies show that intracerebroventricular injection with AAV2/1 on neonatal day P0 results in widespread CNS expression but the biodistribution is limited if injected beyond neonatal day P1. To extend these observations we explored the effect of timing of injection on tropism and biodistribution of six commonly used pseudotyped AAVs delivered in the cerebral ventricles of neonatal mice. We demonstrate that AAV2/8 and 2/9 resulted in the most widespread biodistribution in the brain. Most serotypes showed varying biodistribution depending on the day of injection. Injection on neonatal day P0 resulted in mostly neuronal transduction, whereas administration in later periods of development (24-84 hours postnatal) resulted in more non-neuronal transduction. AAV2/5 showed widespread transduction of astrocytes irrespective of the time of injection. None of the serotypes tested showed any microglial transduction. This study demonstrates that both capsid serotype and timing of injection influence the regional and cell-type distribution of AAV in neonatal rodents, and emphasizes the utility of pseudotyped AAV vectors for translational gene therapy paradigms.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 23825679 · DOI · PMC3692458
CRISPR typing and subtyping for improved laboratory surveillance of Salmonella infections [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Laboratory surveillance systems for salmonellosis should ideally be based on the rapid serotyping and subtyping of isolates.
- Closing excerpt
- An open web-accessible database was set up, providing a serotype/spacer dictionary and an international tool for strain tracking based on this innovative, powerful typing and subtyping tool.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (136 words)
Laboratory surveillance systems for salmonellosis should ideally be based on the rapid serotyping and subtyping of isolates. However, current typing methods are limited in both speed and precision. Using 783 strains and isolates belonging to 130 serotypes, we show here that a new family of DNA repeats named CRISPR (clustered regularly interspaced short palindromic repeats) is highly polymorphic in Salmonella. We found that CRISPR polymorphism was strongly correlated with both serotype and multilocus sequence type. Furthermore, spacer microevolution discriminated between subtypes within prevalent serotypes, making it possible to carry out typing and subtyping in a single step. We developed a high-throughput subtyping assay for the most prevalent serotype, Typhimurium. An open web-accessible database was set up, providing a serotype/spacer dictionary and an international tool for strain tracking based on this innovative, powerful typing and subtyping tool.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 22623967 · DOI · PMC3356390
SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Streptococcus pneumoniae is responsible for 240 000-460 000 deaths in children under 5 years of age each year.
- Closing excerpt
- com/sanger-pathogens/seroba.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (183 words)
Streptococcus pneumoniae is responsible for 240 000-460 000 deaths in children under 5 years of age each year. Accurate identification of pneumococcal serotypes is important for tracking the distribution and evolution of serotypes following the introduction of effective vaccines. Recent efforts have been made to infer serotypes directly from genomic data but current software approaches are limited and do not scale well. Here, we introduce a novel method, SeroBA, which uses a k-mer approach. We compare SeroBA against real and simulated data and present results on the concordance and computational performance against a validation dataset, the robustness and scalability when analysing a large dataset, and the impact of varying the depth of coverage on sequence-based serotyping. SeroBA can predict serotypes, by identifying the cps locus, directly from raw whole genome sequencing read data with 98 % concordance using a k-mer-based method, can process 10 000 samples in just over 1 day using a standard server and can call serotypes at a coverage as low as 15-21×. SeroBA is implemented in Python3 and is freely available under an open source GPLv3 licence from: https://github.com/sanger-pathogens/seroba.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 29870330 · DOI · PMC6113868
Accurate serotype identification of Streptococcus pneumoniae using nanopore Cas9-targeted serotype identification (nCATSerotyping) [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Streptococcus pneumoniae (pneumococcus) is a leading cause of community-acquired pneumonia and invasive diseases, particularly among children and the elderly.
- Closing excerpt
- Furthermore, the identification of misclassified oral streptococci highlights the diagnostic precision needed for accurate pneumococcal surveillance, ensuring that epidemiological data accurately reflect true pneumococcal disease burden and serotype distribution patterns.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (362 words)
Streptococcus pneumoniae (pneumococcus) is a leading cause of community-acquired pneumonia and invasive diseases, particularly among children and the elderly. The introduction of pneumococcal conjugate vaccines has significantly reduced invasive pneumococcal disease, but the prevalence of non-vaccine serotypes and newly emerging serotypes is increasing globally. Thus, accurate serotyping is essential for epidemiological surveillance and the development of next-generation multivalent pneumococcal vaccines. Conventional serotyping methods, including multiplex polymerase chain reaction (mPCR), monoclonal antibody (mAb) assays, and Quellung reaction using rabbit antisera, are limited by serotype coverage and cross-reactivity, making the detection of new or emerging serotypes challenging. In this study, we developed a nanopore Cas9-targeted serotyping (nCATSerotyping) platform, which employs Cas9-mediated enrichment of the capsular polysaccharide synthesis locus followed by Oxford Nanopore sequencing. Applying this method to 276 clinical pneumococcal isolates collected in South Korea (2018-2020), we achieved a serotyping success rate of 97.10% (268/276), significantly outperforming conventional methods such as mAb and mPCR, which identified only 76.45% (211/276) of isolates. Whole-genome sequencing of the remaining eight non-typeable isolates revealed them to be non-pneumococcal (oral streptococci), confirming 100% accuracy for S. pneumoniae serotyping. Importantly, our method identified emerging and underrepresented serotypes, including serotype 13 and null capsule clade strains. nCATSerotyping offers a rapid, accurate, and comprehensive solution for pneumococcal serotyping, with significant advantages in identifying novel and non-typeable strains. This scalable platform will be a valuable tool for global serotype surveillance and next-generation multivalent pneumococcal vaccine development.IMPORTANCEAccurate pneumococcal serotyping is critical for vaccine development and epidemiological surveillance, particularly as non-vaccine serotypes emerge following widespread pneumococcal conjugate vaccine implementation. Current serotyping methods face significant limitations in coverage and accuracy, identifying around 76% of pneumococcal isolates and failing to detect emerging serotypes like serotype 13 and null capsule clades. The nanopore Cas9-targeted serotyping platform addresses these critical gaps by achieving 100% serotyping accuracy for confirmed Streptococcus pneumoniae isolates while identifying previously undetectable strains that conventional methods missed. This comprehensive approach is essential for monitoring vaccine effectiveness, understanding serotype replacement patterns, and informing next-generation vaccine development strategies. Furthermore, the identification of misclassified oral streptococci highlights the diagnostic precision needed for accurate pneumococcal surveillance, ensuring that epidemiological data accurately reflect true pneumococcal disease burden and serotype distribution patterns.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41467797 · DOI · PMC12892971
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Serotype replacement in disease after pneumococcal vaccination [5]
- Research article Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project [6]
- Research article Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes [7]
- Research article Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis [8]
- Research article The influence of virus structure on antibody responses and virus serotype formation [9]
- Research article Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children [10]
References
- Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, et al.. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. . 2013. PMID 23825679 · DOI · PMC3692458
- Fabre L, Zhang J, Guigon G, Le Hello S, Guibert V, Accou-Demartin M, et al.. CRISPR typing and subtyping for improved laboratory surveillance of Salmonella infections. . 2012. PMID 22623967 · DOI · PMC3356390
- Epping L, van Tonder AJ, Gladstone RA, The Global Pneumococcal Sequencing Consortium, Bentley SD, Page AJ, et al.. SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data. . 2018. PMID 29870330 · DOI · PMC6113868
- Ji HJ, Jang A-Y, Han SH, Kim M-K, Lamien CE, Wijewardana V, et al.. Accurate serotype identification of Streptococcus pneumoniae using nanopore Cas9-targeted serotype identification (nCATSerotyping). . 2026. PMID 41467797 · DOI · PMC12892971
- Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011. PMID 21492929 · DOI · PMC3256741
- Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al.. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010. PMID 20957191 · DOI · PMC2950132
- Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis. 1985. PMID 2412271 · DOI
- Muir P, Kämmerer U, Korn K, Mulders MN, Pöyry T, Weissbrich B, et al.. Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis. Clin Microbiol Rev. 1998. PMID 9457433 · DOI · PMC121380
- Bachmann MF, Zinkernagel RM. The influence of virus structure on antibody responses and virus serotype formation. Immunol Today. 1996. PMID 8991286 · DOI
- Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet. 2001. PMID 11289365 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-11-04; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-11-04.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.